Search

Displaying results 3121 - 3130 of 6951 in total
  1. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [L46342,L46387] Later on, the FDA approved pegunigalsidase alfa for the treatment of adult patients with Fabry disease that same month.[L46432,L46437] … [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease.

  2. Drug

    Technetium Tc-99m pertechnetate

    go.drugbank.com/drugs/DB09314
    ApprovedInvestigational

    Currently marketed as the product Drytec, technetium-99m pertechnetate is indicated for imaging of the following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux … supplied in a hospital setting through the use of a technetium-99m generator, whereby technetium exits the generator in the form of the pertechnetate ion, TcO4−, which can be extracted and promptly used for

  3. Drug

    ANA975

    go.drugbank.com/drugs/DB06490
    Experimental

    ANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.

  4. Drug

    Methocarbamol

    go.drugbank.com/drugs/DB00423
    ApprovedInvestigationalVet approved

    Methocarbamol was developed in the early 1950s as a treatment for muscle spasticity and the associated pain.[A178441,A178450] It is a guaiacol glyceryl ether. … [A178450] Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts

  5. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    Treatment options then become limited, and alternate treatments for the lymphoma are required to control disease progression. … It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.

  6. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023.

  7. Drug

    Lactic acid

    go.drugbank.com/drugs/DB04398
    ApprovedInvestigationalVet approved

    A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and ...

    Mixtures: Dianeal for Peritoneal Dialysis, Dianeal for Peritoneal Dialysis
  8. Drug

    Tetrabenazine

    go.drugbank.com/drugs/DB04844
    Approved

    A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. ...

  9. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  10. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis. … Eplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery.